Fly News Breaks for December 26, 2019
Dec 26, 2019 | 09:32 EDT
Cantor Fitzgerald analyst Alethia Young downgraded Spectrum to Neutral from Overweight with a price target of $4, down from $17, after the company announced that the pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously treated non-small cell lung cancer patients with EGFR exon 20 insertion mutations was not met in Cohort 1.
News For SPPI From the Last 2 Days
There are no results for your query SPPI